Cancer is one of the most difficult ailments in the world and slowly cancer surpassing cardiovascular disease as the leading cause of death. There were an estimated 18 million cancer cases around the world in 2018, among them lung and breast cancers are the most common cancers. The currently available cancer therapies still have various limitations, such as multi-drug resistance, undesired off-target effects, and unpredictable efficacies. Consequently, much effort has been invested into finding robust anti-cancer agents that are more selective and less toxic. The emerging molecular targets and signal pathways enable the development of novel strategies for the rational design of new anticancer agents. Along those lines, we have obtained some interesting preliminary results on anticancer activity of our compounds, particularly towards non-small cell lung cancers. Currently we are working on designing and synthesizing new libraries of five and six membered azole compounds with different substitution patterns and evaluate them for anticancer activity. Once we synthesize the designed products and confirm their structures by analytical techniques, we will evaluate their anticancer activity and identify their target using variety of biological assays. The long-term goal of this project is to find novel anticancer agents for lung cancer therapy. In addition to that, we will be developing several synthetic approaches that will ultimately provide new chemical tools for the diverse range of synthetic chemists and biomedical researchers in academia as well as in pharmaceutical industry.